Too slow, too expensive, too ineffective. Researchers are crying out for a new battle plan that will aim high and deliver on the great promise of personalised therapies. We all want to see target patient populations identified early, and marketing access denied to drugs that aren’t ever going to be much use. The question is, how?
Leave a Reply